EU Regulators Approve First and Only Adrenaline Nosal Spay for Emergency Treatments nextdigitalhealth.com

The European Commission has approved the first and only no-needle adrenaline-based nosal spray, EURneffy®, to treat severe cases of allergenic reactions commonly known as anaphylaxis.

Developed by ARS Pharmaceuticals, Inc., the nosal spray offers EU residents living with severe allergic reactions the first alternative method for adrenaline delivery in over 30 years.